QuellTX Logo
04/08/21

Quell Therapeutics to Present at the 2021 Wedbush Pacgrow Healthcare Virtual Conference

London, UK and Boston, MA, USA, August 4, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that Iain McGill, Chief Executive Officer of Quell Therapeutics, will participate in a panel discussion, Out of Body Experience – Transplant: Two Genotypes Living in Harmony, at the Wedbush Pacgrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 7:55 p.m. BST (2:55 p.m. ET).

About Quell Therapeutics

Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches.

Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. www.quell-tx.com.

Contacts

Media: Mark Swallow, Frazer Hall, Eleanor Perkins
MEDiSTRAVA Consulting
+44 207 638 9571
Quell-Tx@Medistrava.com

Investors: Christina Tartaglia
Stern Investor Relations, Inc.
+1 212 362 1200
christina@sternir.com

09/06/23

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as well as its deep therapeutic area knowledge Collaboration focused on two autoimmune disease areas – Type 1 Diabetes and…...

Read More
22/11/22

Quell Therapeutics to Present at Upcoming Investor Conferences in 2022

London, UK and Boston, MA, USA – November 22, 2022 – Quell Therapeutics Ltd (“Quell”), a leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will participate…...

Read More
21/11/22

Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer

Adds significant clinical, translational science and immunology expertise to leadership team as Quell prepares to advance QEL-001 into its first clinical trial and progresses its CAR-Treg cell therapy pipeline programs in Auto-Immunity and Neuro-Inflammation London, UK – November 21, 2022…...

Read More